Reviewing NEXGEL (NXGL) & Its Rivals

Posted by on Apr 9th, 2023

NEXGEL (NASDAQ:NXGL – Get Rating) is one of 229 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare NEXGEL to related companies based on the strength of its analyst recommendations, dividends, valuation, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares NEXGEL and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NEXGEL $2.05 million -$4.75 million -1.62
NEXGEL Competitors $1.12 billion $54.73 million -3.25

NEXGEL’s peers have higher revenue and earnings than NEXGEL. NEXGEL is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

1.9% of NEXGEL shares are held by institutional investors. Comparatively, 45.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 25.2% of NEXGEL shares are held by insiders. Comparatively, 14.5% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

NEXGEL has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, NEXGEL’s peers have a beta of 1.37, suggesting that their average share price is 37% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NEXGEL and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL 0 0 0 0 N/A
NEXGEL Competitors 1023 3636 7839 183 2.57

NEXGEL currently has a consensus price target of $5.00, suggesting a potential upside of 262.32%. As a group, “Surgical & medical instruments” companies have a potential upside of 22.06%. Given NEXGEL’s higher probable upside, analysts plainly believe NEXGEL is more favorable than its peers.

Profitability

This table compares NEXGEL and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NEXGEL -231.63% -53.47% -38.40%
NEXGEL Competitors -495.28% -105.70% -25.30%

NEXGEL Company Profile

(Get Rating)

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

Receive News & Ratings for NEXGEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NEXGEL and related companies with MarketBeat.com's FREE daily email newsletter.